Weak Q1 growth masks H2 ambitions; guidance intact but under pressure

Exports +27.7% YoY; domestic -3.1%; Q4 inventory buildup drove export surge

EBITDA ₹40.8 Cr with 11.8% margin; growth of 18.8% YoY verified

Only 2 of 3 MoU products at commercial lot stage in Q1; volume ramp pushed to Q4

Q1 at 8.7%; requires H2 to deliver 18-24% to hit midpoint; macro headwinds acknowledged

Claims strong order book for Q2-Q4 but Q1 delivery only 8.7%; unverified on H2

2 of 3 MoU products at commercial lot stage Q1; volume ramp Q4 vs. earlier (3-6 month customer testing cycle)

Q1 at 8.7% vs. 15-20% guidance; requires H2 to deliver 18-24% to hit midpoint

At 14% in Q1 (growing 40% YoY), targeting 15-18% for FY27; on track but not ahead of target

Reaffirmed gradual improvement to 15% over 2-3 years from ~12%; on track

Reaffirmed goal to start CAPEX in FY27; no site secured yet but commitment firm

3-4% from price increase; balance from volume growth

Derabassi ~85%; Lalru ~71-72%; expect improvement in Q2-Q3

Targeting 15-18% contribution from new products for full year FY27

Yes, goal is to start Greenfield CAPEX in FY27

Cyclical; expect increase in H1, normalize back to ~62 range by year-end

R&D facility doubled in 2 years; targeting 4-5 products per year; some ₹8-10 Cr, others ₹40-50 Cr potential over 3-4 years

Targeting 15-18% for FY27; year-on-year increase visible; gradual ramp to 20% over time

Top 5 ~60-65%; top 10 ~75% of revenue

Yes, ₹4-4.5 Cr one-time reward to 3 people on prior 3-4 years performance

No; export growth from better planning (Q4 inventory buildup); new products are domestic-focused with better margins

Yes, maintaining guidance; pursuing process improvements and novel technologies in parallel

Dynamic situation; no material disruption Q1 or expected Q2; remain vigilant on raw materials and solvents

2 of 3 supplied commercial lots (2-5 tons each); being tested by customers; 3-6 month testing cycle; volume ramp Q4 FY27

Expanding customer base; targeting 2-3 new customers with multi-year contracts in next 2-3 quarters; current 50:50 mix with catalog products

Yes; H2 will be much better; H1 is industry peak due to concentrated demand

~70% from Europe; remaining from US, Latin America, Japan

Price pressure visible; expect 5-8% demand reduction; taking proactive pricing and contracting steps to maintain volume

Better planning; built inventory in Q4 to capture peak-season demand; now normalized

Yes; Q1 difficult seasonally; planning much better H2 for 15-20% growth

Mix of products; intermediates for agrochemicals and pharmaceuticals

Efficiency improvements are sustainable; pricing is market-driven and may not be sustainable

Commercial launch achieved Q1; customer testing takes 3-6 months; volume ramp gradual after approval

Targeting 15-18% for FY27; will not provide specific breakup; products are dynamic situation

FY26 base ₹1,030 Cr; FY27 at 15-18% growth = ~₹1,200 Cr; math implies 15% CAGR on base

Two products; ₹10-20 Cr in year 1 of launch; ₹40-50 Cr potential over 3-4 years at peak

Yes, increased interest from Europe and Japan for India sourcing; domestic interest also growing; Japanese typically multi-year contracts once onboard

CDMO and catalog remain similar (50:50 now); agrochemicals ~65-70% and will remain dominant

Q1 only 8.7%; requires H2 to deliver 18-24% to achieve midpoint; seasonality argument used

Currently 11.8%; driven by new products, process improvements, and novel technologies

No site secured yet; Lalru manufacturing block civil works commenced; Q2-Q3 investment planned

Weak Indian monsoon delaying sowing reduces agrochemical demand. European adverse weather (long hot season) delaying customer buying decisions. Could derail 15-20% FY27 growth target.

Geopolitical tension in Middle East increased energy and freight costs. Supply chain remains fragile and sensitive to cost shocks. Solvents and chemical availability volatile.

Products coming off-patent face rapid price pressure from Chinese competitors. Forces continuous cost reduction, process innovation, and technology investment. Pricing power erodes on legacy portfolio.

2 of 3 MoU products only at commercial lot stage in Q1; volume ramp delayed to Q4 FY27. Customer testing cycles (3-6 months) delay approval and revenue recognition. Timeline slippage vs. prior guidance.

Top 5 customers represent 60-65% of revenue; top 10 represent 75%. High concentration risk. Loss of major customer or adverse pricing negotiation could significantly impact revenue and margins.

Q1 revenue growth only 8.7% vs. 15-20% FY27 guidance. Requires H2 to deliver 18-24% growth to hit midpoint. Aggressive H2 target given macro headwinds and near-term supply chain challenges.

3-4% of 9% Q1 revenue growth came from pricing. Management admits pricing gains likely not sustainable as markets adjust. Implies true underlying volume growth of only 5-6%, which is weak.